

course, came here Thursday and wanted us to pass \$700 billion, and they want us to pass this very soon. So "rapidly" sometimes is in the eye of the beholder.

The point is, you're correct; there was a discrepancy. We think that was not fair. It was not intentional. But Mr. ARCURI, who gave the information to the minority and the information that was on the Web site, was not correct. We think, under those circumstances, in fairness to all, that we ought to redo this, and that's what we intend to do. And we discussed it with your leadership and we all agreed that that was the right thing to do.

Mr. SESSIONS. Continuing my reservation, I would say to the gentleman that we're not in any hurry over here in doing it right. The Republican Party is not in a rush, and we would wish for us to do very deliberately that which needs to be done.

Mr. HASTINGS of Washington. Would the gentleman yield?

Mr. SESSIONS. I would yield to the gentleman from Washington.

Mr. HASTINGS of Washington. I appreciate the gentleman yielding.

Mr. Speaker, this is really very, very important because we are at the last days of this session and we know there is a rush to try to get things done. And I understand that it was a book-keeping—it wasn't intentional. I understand all of that, we've been through this before. But the significance of this, and it needs to be understood by this body as we are being asked in the future to make some big decisions, the difference in this little error was \$100 million. It wasn't small potatoes, so to speak. And I just want to say that the right thing to do—and I hope this is what's going to happen—is that the Rules Committee goes back upstairs and reports it out correctly so we can have the text. But I think that point needs to be made. And I appreciate the gentleman for yielding.

Mr. HOYER. Would the gentleman yield?

Mr. SESSIONS. I would yield to the gentleman.

Mr. HOYER. I told the gentleman from Washington that's exactly what I'm trying to do, which is why I thought it best to obviate the vote so we can do exactly what you've suggested. I've discussed it with your leadership and they've agreed. I hope we can do that, and I hope there's not an objection.

Mr. SESSIONS. Mr. Speaker, I withdraw my reservation.

The SPEAKER pro tempore. Without objection, the vote on adoption of the resolution is vacated.

There was no objection.

Mr. HOYER. Mr. Speaker, I ask unanimous consent that both the vote on the adoption of the rule and the vote on the previous question be vacated.

The SPEAKER pro tempore. Is there objection to the request of the gentleman from Maryland?

There was no objection.

Mr. ARCURI. Mr. Speaker, under the rules, I withdraw House Resolution 1501.

The SPEAKER pro tempore. The resolution is withdrawn.

□ 1545

#### ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE

The SPEAKER pro tempore. Without objection, 5-minute voting will continue.

There was no objection.

#### UNITED STATES COMMITMENT TO PRESERVATION OF RELIGIOUS AND CULTURAL SITES

The SPEAKER pro tempore. The unfinished business is the vote on the motion to suspend the rules and agree to the concurrent resolution, H. Con. Res. 255, as amended, on which the yeas and nays were ordered.

The Clerk read the title of the concurrent resolution.

The SPEAKER pro tempore. The question is on the motion offered by the gentleman from New York (Mr. CROWLEY) that the House suspend the rules and agree to the concurrent resolution, H. Con. Res. 255, as amended.

This will be a 5-minute vote.

The vote was taken by electronic device, and there were—yeas 414, nays 1, not voting 18, as follows:

	[Roll No. 641]	YEAS—414
Abercrombie	Brown-Waite, Davis (KY)	Davis (KY)
Ackerman	Ginny Davis, Lincoln	Jordan
Aderholt	Buchanan Davis, Tom	Kagen
Akin	Burgess Deal (GA)	Kanjorski
Alexander	Burton (IN) DeFazio	Kaptur
Allen	Butterfield DeGette	Keller
Altmine	Buyer Delahunt	Kennedy
Andrews	Calvert DeLauro	Kildee
Arcuri	Camp (MI) Dent	Kilpatrick
Baca	Campbell (CA) Diaz-Balart, L.	Kind
Bachmann	Cannon Diaz-Balart, M.	King (IA)
Baird	Cantor Dicks	King (NY)
Baldwin	Capito Dingell	Kingston
Barrett (SC)	Capps Doggett	Kirk
Barrow	Capuano Donnelly	Klein (FL)
Bartlett (MD)	Cardoza Doolittle	Kline (MN)
Barton (TX)	Carnahan Doyle	Knollenberg
Bean	Carney Drake	Langevin
Becerra	Carson Dreier	Larsen (WA)
Berkley	Carter Duncan	Larson (CT)
Berman	Castle Edwards (MD)	Emanuel
Berry	Castor Edwards (TX)	Latham
Biggert	Cazayoux Ehlers	LaHood
Bilbray	Chabot Ellison	Lamborn
Bilirakis	Chandler Ellsworth	Lampson
Bishop (GA)	Childers Emanuel	Langevin
Bishop (NY)	Clarke Emerson	Putnam
Bishop (UT)	Clay Engel	Rangel
Blackburn	Cleaver English (PA)	Price (GA)
Blumenauer	Clyburn Eshoo	Price (NC)
Blunt	Coble Etheridge	Pomero
Bonner	Cohen Fallin	Porter
Bono Mack	Cole (OK) Farr	Price (OH)
Boozman	Conaway Fattah	Putnam
Boren	Cooper Feeney	Rahall
Boswell	Costa Ferguson	Ramanovich
Boucher	Costello Filner	Rahall
Boustany	Courtney Flake	Ramanovich
Boyd (FL)	Crenshaw Forbes	Rahall
Boysda (KS)	Crowley Fortenberry	Rahall
Brady (PA)	Cuellar Fossella	Rahall
Brady (TX)	Culberson Foster	Rahall
Braley (IA)	Cummings Foxx	Rahall
Brown (GA)	Davis (AL) Franks (AZ)	Rahall
Brown (SC)	Davis (CA) Frelinghuysen	Rahall
Brown, Corrine	Davis (IL) Gallegly	Rahall

Garrett (NJ)	Lynch	Rothman
Geriach	Mack	Royal-Allard
Giffords	Mahoney (FL)	Royce
Gilchrest	Maloney (NY)	Ruppersberger
Gillibrand	Manzullo	Rush
Gingrey	Marchant	Ryan (OH)
Gohmert	Markey	Ryan (WI)
Gonzalez	Marshall	Salazar
Goode	Matheson	Sali
Goodlatte	Matsui	Sánchez, Linda
Gordon	McCarthy (CA)	T.
Granger	McCarthy (NY)	Sanchez, Loretta
Graves	McCaull (TX)	Scarbones
Green, Al	McCullom (MN)	Scalise
Green, Gene	Saxton	Schakowsky
Grijalva	McCotter	Shadegg
Gutierrez	McCrery	Schiff
Hall (NY)	McDermott	Schmidt
Hall (TX)	McGovern	Schwartz
Hare	McHenry	Scott (GA)
Harman	McHugh	Scott (VA)
Hastings (WA)	McIntyre	Sensenbrenner
Hayes	McKeon	Serrano
Heller	McMorris	Sessions
Hensarling	Rodgers	Sestak
Herger	McNerney	Shadegg
Herseth Sandlin	McNulty	Shays
Higgins	Meek (FL)	Shea-Porter
Hill	Meeks (NY)	Sherman
Hinchey	Melancon	Shimkus
Hinojosa	Micahaud	Shuster
Hirono	Miller (MI)	Simpson
Hobson	Miller (NC)	Sires
Hodes	Miller, Gary	Skelton
Hoekstra	Miller, George	Slaughter
Holden	Mitchell	Smith (NE)
Holt	Mollohan	Smith (NJ)
Honda	Moore (KS)	Smith (TX)
Hooley	Moore (WI)	Smith (WA)
Hulshof	Moran (KS)	Snyder
Hunter	Moran (VA)	Solis
Inglis (SC)	Murphy (CT)	Space
Inslee	Murphy, Patrick	Speier
Issa	Murphy, Tim	Spratt
Jackson (IL)	Murtha	Stark
Jackson-Lee (TX)	Musgrave	Stearns
Jefferson	Myrick	Stupak
Johnson (GA)	Nadler	Tullivan
Johnson (IL)	Neal (MA)	Tanner
Johnson, E. B.	Neugebauer	Tauscher
Johnson, Sam	Nunes	Taylor
Jones (NC)	Oberstar	Terry
Jordan	Obey	Thompson (CA)
Kagen	Olver	Thompson (MS)
Kanjorski	Ortiz	Thornberry
Kaptur	Pallone	Tihart
Keller	Pascarella	Tiberi
Kennedy	Pastor	Tierney
Kildee	Payne	Towns
Kilpatrick	Pearce	Tsangas
Kind	Pence	Turner
King (IA)	Perlmutter	Udall (NM)
King (NY)	Peterson (MN)	Upton
Kingston	Peterson (PA)	Van Hollen
Kirk	Petri	Viscosky
Klein (FL)	Pickering	Walberg
Kline (MN)	Pitts	Walenzquez
Knollenberg	Platts	Wasserman
Koellnerberg	Poe	Walberg
Lamborn	Price (GA)	Walenzquez
Lampson	Price (NC)	Wamp
Langevin	Pryce (OH)	Wasserman
Larsen (WA)	Putnam	Walenzquez
Larson (CT)	Radanovich	Walenzquez
Latham	Rahall	Watson
LaTourette	Ramstad	Watt
Latta	Rangel	Weiner
Leahy	Regula	Welch (VT)
Levin	Rehberg	Weller
Lewis (CA)	Reichert	Westmoreland
Lewis (GA)	Renzi	Wexler
Lewis (KY)	Reyes	Wilson (NM)
Linder	Reynolds	Wilson (OH)
Lipinski	Richardson	Wilson (SC)
LoBiondo	Rodriguez	Wittman (VA)
Loebsack	Rogers (AL)	Wolf
Lofgren, Zoe	Rogers (KY)	Woolsey
Lowey	Rohrabacher	Wu
Lucas	Ros-Lehtinen	Yarmuth
Lungren, Daniel E.	Roskam	Young (AK)
Ross	Ross	Young (FL)

NAYS—1

Paul

## NOT VOTING—18

Bachus	Everett	Napolitano
Boehner	Frank (MA)	Shuler
Conyers	Hastings (FL)	Souder
Cramer	Hoyer	Udall (CO)
Cubin	Israel	Weldon (FL)
Davis, David	Miller (FL)	Whitfield (KY)

□ 1604

Mrs. BACHMANN changed her vote from “nay” to “yea.”

So (two-thirds being in the affirmative) the rules were suspended and the concurrent resolution, as amended, was agreed to.

The result of the vote was announced as above recorded.

A motion to reconsider was laid on the table.

Stated for:

Mr. BACHUS. Madam Speaker, on September 25, 2008, I missed rollcall vote 641 while attending a meeting at the White House to discuss the Nation’s financial crisis. Had I been present, I would have voted “yea” on rollcall 641.

---

**ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE**

The SPEAKER pro tempore (Ms. BALDWIN). Pursuant to clause 8 of rule XX, the Chair will postpone further proceedings today on motions to suspend the rules on which a recorded vote or the yeas and nays are ordered, or on which the vote is objected to under clause 6 of rule XX.

Record votes on postponed questions will be taken later today.

---

**BREAST CANCER AND ENVIRONMENTAL RESEARCH ACT OF 2008**

Mr. PALLONE. Madam Speaker, I move to suspend the rules and pass the bill (H.R. 1157) to amend the Public Health Service Act to authorize the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer, as amended.

The Clerk read the title of the bill.

The text of the bill is as follows:

H.R. 1157

*Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,*

**SECTION 1. SHORT TITLE.**

This Act may be cited as the “Breast Cancer and Environmental Research Act of 2008”.

**SEC. 2. EXPANDING COLLABORATIVE RESEARCH ON BREAST CANCER AND THE ENVIRONMENT.**

(a) IN GENERAL.—Subpart 1 of part C of title IV of the Public Health Service Act (42 U.S.C. 285 et seq.) is amended by adding at the end the following:

**“SEC. 417F. INTERAGENCY BREAST CANCER AND ENVIRONMENTAL RESEARCH COORDINATING COMMITTEE.**

“(a) INTERAGENCY BREAST CANCER AND ENVIRONMENTAL RESEARCH COORDINATING COMMITTEE.—

“(1) ESTABLISHMENT.—Not later than 6 months after the date of the enactment of this section, the Secretary shall establish a committee, to be known as the Interagency Breast

Cancer and Environmental Research Coordinating Committee (in this section referred to as the ‘Committee’).

“(2) DUTIES.—The Committee shall—

“(A) share and coordinate information on existing research activities, and make recommendations to the National Institutes of Health and other Federal agencies regarding how to improve existing research programs, that are related to breast cancer research;

“(B) develop a comprehensive strategy and advise the National Institutes of Health and other Federal agencies in the solicitation of proposals for collaborative, multidisciplinary research, including proposals to evaluate environmental and genomic factors that may be related to the etiology of breast cancer that would—

“(i) result in innovative approaches to study emerging scientific opportunities or eliminate knowledge gaps in research to improve the research portfolio;

“(ii) outline key research questions, methodologies, and knowledge gaps;

“(iii) expand the number of research proposals that involve collaboration between 2 or more national research institutes or national centers, including proposals for Common Fund research described in section 402(b)(7) to improve the research portfolio; and

“(iv) expand the number of collaborative, multidisciplinary, and multi-institutional research grants;

“(C) develop a summary of advances in breast cancer research supported or conducted by Federal agencies relevant to the diagnosis, prevention, and treatment of cancer and other diseases and disorders; and

“(D) not later than 2 years after the date of the establishment of the Committee, make recommendations to the Secretary—

“(i) regarding any appropriate changes to research activities, including recommendations to improve the research portfolio of the National Institutes of Health to ensure that scientifically-based strategic planning is implemented in support of research priorities that impact breast cancer research activities;

“(ii) to ensure that the activities of the National Institutes of Health and other Federal agencies, including the Department of Defense, are free of unnecessary duplication of effort;

“(iii) regarding public participation in decisions relating to breast cancer research to increase the involvement of patient advocacy and community organizations representing a broad geographical area;

“(iv) on how best to disseminate information on breast cancer research progress; and

“(v) on how to expand partnerships between public entities, including Federal agencies, and private entities to expand collaborative, cross-cutting research.

“(3) RULE OF CONSTRUCTION.—For the purposes of the Committee, when focusing on research to evaluate environmental and genomic factors that may be related to the etiology of breast cancer, nothing in this section shall be construed to restrict the Secretary from including other forms of cancer, as appropriate, when doing so may advance research in breast cancer or advance research in other forms of cancer.

“(4) MEMBERSHIP.—

“(A) IN GENERAL.—The Committee shall be composed of the following voting members:

“(i) Not more than 7 voting Federal representatives as follows:

“(I) The Director of the Centers for Disease Control and Prevention.

“(II) The Director of the National Institutes of Health and the directors of such national research institutes and national centers (which may include the National Institute of Environmental Health Sciences) as the Secretary determines appropriate.

“(III) One representative from the National Cancer Institute Board of Scientific Advisors, appointed by the Director of the National Cancer Institute.

“(IV) The heads of such other agencies of the Department of Health and Human Services as the Secretary determines appropriate.

“(V) Representatives of other Federal agencies that conduct or support cancer research, including the Department of Defense.

“(ii) 12 additional voting members appointed under subparagraph (B).

“(B) ADDITIONAL MEMBERS.—The Committee shall include additional voting members appointed by the Secretary as follows:

“(i) 6 members shall be appointed from among scientists, physicians, and other health professionals, who—

“(I) are not officers or employees of the United States;

“(II) represent multiple disciplines, including clinical, basic, and public health sciences;

“(III) represent different geographical regions of the United States;

“(IV) are from practice settings, academia, or other research settings; and

“(V) are experienced in scientific peer review process.

“(ii) 6 members shall be appointed from members of the general public, who represent individuals with breast cancer.

“(C) NONVOTING MEMBERS.—The Committee shall include such nonvoting members as the Secretary determines to be appropriate.

“(5) CHAIRPERSON.—The voting members of the Committee shall select a chairperson from among such members. The selection of a chairperson shall be subject to the approval of the Director of NIH.

“(6) MEETINGS.—The Committee shall meet at the call of the chairperson of the Committee or upon the request of the Director of NIH, but in no case less often than once each year.

“(b) REVIEW.—The Secretary shall review the necessity of the Committee in calendar year 2011 and, thereafter, at least once every 2 years.”.

(b) AUTHORIZATION OF APPROPRIATIONS.—For the purpose of carrying out research activities under title IV of the Public Health Service Act, including section 417F of such Act as added by subsection (a), there are authorized to be appropriated \$40,000,000 for each of fiscal years 2009 through 2012. Amounts authorized to be appropriated under the preceding sentence shall be in addition to amounts otherwise authorized to be appropriated for such purpose under section 402A of the Public Health Service Act (42 U.S.C. 282a).

The SPEAKER pro tempore. Pursuant to the rule, the gentleman from New Jersey (Mr. PALLONE) and the gentleman from Georgia (Mr. DEAL) each will control 20 minutes.

The Chair recognizes the gentleman from New Jersey.

**GENERAL LEAVE**

Mr. PALLONE. Madam Speaker, I ask unanimous consent that all Members may have 5 legislative days to revise and extend their remarks and include extraneous material on the bill under consideration.

The SPEAKER pro tempore. Is there objection to the request of the gentleman from New Jersey?

There was no objection.

Mr. PALLONE. Madam Speaker, I yield myself such time as I may consume.

Madam Speaker, I rise in strong support of H.R. 1157, the Breast Cancer and Environmental Research Act, legislation introduced by Representatives NITA LOWEY and SUE MYRICK.

According to the Centers for Disease Control and Prevention, the CDC, breast cancer is the second most common form of cancer in women. Each